Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Low Iodine Diet Does Not Improve the Efficacy of Radioiodine for the Treatment of Graves’ Disease
source: Archives of Endocrinology and Metabolism
year: 2015
authors: Santarosa VA, Orlandi DM, Fiorin LB, Kasamatsu TS, Furuzawa GK1, Kunii IS, Padovani RP, Marone MM, Castiglioni ML, Vieira JG, Maciel RM, Dias-da-Silva MR, Martins JR
summary/abstract:Objective:
Consuming a low-iodine diet (LID) is a widely accepted practice before administering radioiodine (131I) to evaluate and to treat thyroid disease. Although this procedure is well established for the management of patients with differentiated thyroid cancer, its use in patients with benign disease is unclear. So, we aimed to evaluate the influence of a LID on the outcome in patients with Graves’ disease (GD) treated with 131I.
Subjects and Methods:
We evaluated 67 patients with GD who were divided into 2 groups: one group (n = 31) consumed a LID for 1-2 weeks, and the second group (n = 36) was instructed to maintain a regular diet (RD).
Results:
The LID group experienced a 23% decrease in urinary iodine after 1 week on the diet and a significant 42% decrease after 2 weeks on the diet. The majority (53%) of the patients in the LID group had urinary iodine levels that were consistent with deficient iodine intake. However, there was no difference in the rate of hyperthyroidism’s cure between the LID and the RD groups 6 months after 131I therapy. Furthermore, the therapeutic efficacy did not differ in patients with varying degrees of sufficient iodine intake (corresponding urinary iodine levels: < 10 μg/dL is deficient; 10-29.9 μg/dL is sufficient; and > 30 μg/dL is excessive).
Conclusion:
In the present study, we demonstrated that although a LID decreased urinary iodine levels, those levels corresponding with sufficient or a mild excess in iodine intake did not compromise the therapeutic efficacy of 131I for the treatment of GD.
DOI: 10.1590/2359-3997000000082
read more full text
myBinderRelated Content
-
131I-Induced Graves’ Disease in Patients Treated for Toxic Multinodular Goitre: Systematic Review and Descript...Background: Graves’ disease (GD) aris...
-
Radioiodine Treatment for Thyroid DiseaseRadioiodine is a radioactive isotope of ...
-
Cancer Incidence and Mortality After Radioiodine Treatment for Hyperthyroidism: A Population-Based Cohort StudyBackground: Radioiodine is used increas...
-
Optimal Iodine Supplementation During Antithyroid Drug Therapy for Graves’ Disease Is Associated With Lower Re...Objective: A relationship between iodin...
-
Impaired Immune Regulation After Radioiodine Therapy for Graves’ Disease and the Protective Effect of Methimaz...Both therapies for Graves' disease (GD),...
-
Risk Factors of Hepatic Dysfunction in Patients With Graves’ Hyperthyroidism and the Efficacy of 131iodine Tre...Hepatic dysfunction is often observed in...
-
Weight Gain After Treatment of Graves’ Disease in ChildrenObjective: The frequency of and risk fa...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Facebook
Google